Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 26;8(2):e001182. doi: 10.1136/jitc-2020-001182

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Celecoxib blocks indoleamine 2,3 dioxygenase (IDO) but not programmed death ligand-1 (PD-L1) induction and programmed death-1 (PD-1) or IDO blockade does not prevent cyclooxygenase-2 (COX2) induction after cyclic diadenyl monophosphate (CDA) treatment. (A–H) B6 mice bearing Lewis lung carcinoma (LLC) tumors were treated with CDA and celecoxib (A–D), CDA and BMS-986205 (E, F) or CDA and anti-PD1 monoclonal antibodies (mAbs) (G, H). Tumor lesions and tumor-draining lymph nodes (TDLNs) were harvested 24 hours (A–B) or 3 hours (C–H) after the second administration of CDA. IDO activity (A, B), PD-L1 (C, D) or COX2 gene expression (E–H) was assessed. Data are mean±SEM. Data were analyzed using Mann-Whitney U tests, n=4–8. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001. NS, not significant; Vh, vehicle.